Roelof Rongen | CEO
Adolore Biotherapeutics

Mr. Rongen is a serial entrepreneur and R&D / Commercial Development leader with extensive experience across many therapeutic areas and functions. Currently, he is the CEO of neuroscience/gene-therapy company of Adolore BioTherapeutics, Co-Founder and Board Member of a new MSKCC spinout Oncology Company, and Board Member of GRI Bio [Nasdaq:GRI].  He founded and progressed Matinas BioPharma (omega-3 therapeutics and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB); and he was integral to the development and commercialization of multiple blockbuster products such as Humira® and Lovaza®. Prior to founding Matinas BioPharma, Mr. Rongen was the architect behind Trygg Pharma which facilitated Norway’s Aker Group’s entry into the prescription omega-3 business. Before his work with Aker, he was VP for IP and Portfolio Management at Reliant Pharmaceuticals (acquired by GlaxoSmithKline) where he in-licensed Lovaza® and led development and pre-launch activities. Earlier in his career, Mr. Rongen was Global Product Director for Humira® and other Immunology Programs at BASF Pharma (acquired by Abbott/Abbvie). Mr. Rongen started his professional career as a management consultant at Arthur D. Little’s Technology Innovation Management practice in Amsterdam, the Netherlands, followed by his work in New York City as biotech/pharmaceutical consultant at The Wilkerson Group (acquired by IBM). Mr. Rongen holds a Master of Science in Engineering (MSE) in Molecular Sciences graduate degree from Wageningen University in the Netherlands (with Biotechnology/Bio-Process Technology focus), and an MBA from the Kellogg School of Management at Northwestern University.